-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 LPYaQtw29Q3wmQ06x2jrM1yRkH+0SAmtq4sOWq8Q2lcVCd8IHmy7qsIXnOdxzptC
 NxjAQ7MI1EH0eZQPDZDXAQ==

<SEC-DOCUMENT>0001193125-10-068018.txt : 20100326
<SEC-HEADER>0001193125-10-068018.hdr.sgml : 20100326
<ACCEPTANCE-DATETIME>20100326100922
ACCESSION NUMBER:		0001193125-10-068018
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100326
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100326
DATE AS OF CHANGE:		20100326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		10706369

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B>
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of Earliest Event Reported): March&nbsp;26, 2010 </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as
Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200,
Broomfield, CO 80021 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01 Other Events </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>On March&nbsp;26, 2010, ARCA biopharma, Inc., or ARCA, issued a press release announcing that the U.S. Patent and Trademark Office has
issued a patent on methods of treating heart failure patients with bucindolol based on genetic testing. ARCA also announced that on March&nbsp;25, 2010 it submitted a revised clinical study protocol for review under the U.S. Food and Drug
Administration&#146;s Special Protocol Assessment process for the design of a clinical trial to assess the safety and efficacy of Gencaro in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most
favorably to Gencaro. The press release is attached as Exhibit&nbsp;99.1 hereto, the contents of which are incorporated herein by reference. <B> </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman"
SIZE="2"><B>Item&nbsp;9.01 Financial Statements and Exhibits </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma announces patent issued for treating heart failure patients with bucindolol based on genetic testing&#148;, subtitled &#147;revised
request for FDA Special Protocol Assessment for Gencaro development in genotype-defined heart failure population submitted&#148;, dated March&nbsp;26, 2010.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: March&nbsp;26, 2010 </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Patrick M. Wheeler</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick M. Wheeler</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acting Chief Financial Officer</FONT></TD></TR></TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma announces patent issued for treating heart failure patients with bucindolol based on genetic testing&#148;, subtitled &#147;revised
request for FDA Special Protocol Assessment for Gencaro development in genotype-defined heart failure population submitted&#148;, dated March&nbsp;26, 2010.</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g56396g66d16.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman"
SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor Relations&nbsp;&amp; Corporate Communications </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com </U>
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA ANNOUNCES PATENT ISSUED FOR TREATING HEART </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FAILURE PATIENTS WITH BUCINDOLOL BASED ON GENETIC TESTING </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman"
SIZE="2"><B>Revised Request for FDA Special Protocol Assessment for Gencaro<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> Development in </FONT></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Genotype-defined Heart Failure Population Submitted
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, March&nbsp;26, 2010</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically
targeted therapies for heart failure and other cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods of treating heart failure patients with bucindolol based on genetic testing. The
patent (USP# 7,678,824) entitled &#147;Methods for Treatment with Bucindolol Based on Genetic Targeting,&#148; provides protection in the United States for this novel approach to treating patients with heart failure, one of the largest health care
problems in the United States and the rest of the world. ARCA had previously announced the notice of allowance of this patent. Industry sources estimate that approximately 5.7&nbsp;million Americans have heart failure and nearly 670,000 new patients
are diagnosed annually. In addition, heart failure is the underlying reason for approximately 12 to 15&nbsp;million annual visits to physicians, 6.5&nbsp;million annual hospital days and over $37 billion in direct and indirect healthcare costs in
the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are obviously pleased with the USPTO&#146;s issuance of this patent which we believe will extend our
pharmacogenetic intellectual property protection around bucindolol and, if approved for marketing, provide Gencaro market exclusivity into 2025,&#148; said Michael R. Bristow, President and Chief Executive Officer of ARCA. &#147;Chronic heart
failure continues to be a major health care problem, and among the challenges to improving care is the uncertainty of patient responses to drug treatment. We believe that a new heart failure therapy that includes a simple test to identify a
substantial subpopulation of patients more likely to benefit has the potential to help alleviate some of the problems encountered with the current standard of practice.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;25, 2010, ARCA submitted a revised clinical study protocol for review under the U.S. Food and Drug Administration&#146;s (FDA) Special Protocol Assessment (SPA) process for the design of a
clinical trial to assess the safety and efficacy of Gencaro in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. An SPA is an agreement with the FDA that the proposed
trial protocol design, clinical endpoints and statistical analyses are acceptable to support regulatory approval. Any proposed trial protocol must be reviewed and agreed upon with the FDA and the final trial protocol may be significantly different
from the Company&#146;s SPA submission. If ARCA obtains sufficient funding and FDA approval of the SPA, ARCA currently expects it could begin the proposed clinical trial approximately one year after such funding and approval. The FDA has previously
designated as a Fast Track development program the investigation of Gencaro for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Gencaro<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> </FONT></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">
(bucindolol hydrochloride) is a pharmacologically unique beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily. Gencaro is considered part of the
beta-blocker class because of its property of blocking beta-1 as well as beta-2 receptors in the heart, preventing these receptors from binding with other molecules that would otherwise activate the receptor. Because of its mild vasodilator effects,
the Company believes Gencaro is well-tolerated in patients with advanced HF. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The
Company&#146;s lead product candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">
(bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure. ARCA has identified common genetic variations that it believes predict individual patient response to
Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please visit
<U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not
limited to, statements regarding the issuance of, and protection provided by, U.S. Patent 7,678,824 entitled &#147;Methods for Treatment with Bucindolol Based on Genetic Targeting.&#148; and statements regarding the timing and outcome of the
Company&#146;s SPA submission; regulatory review and potential approval of the Company&#146;s New Drug Application for Gencaro; the prospects for ARCA&#146;s providing sufficient information in a timely manner as requested in the FDA&#146;s Complete
Response Letter; and the Company&#146;s ability to fund future operations. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those
projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the
Company&#146;s business objectives and operational requirements; the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of
competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended
December&nbsp;31, 2009 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g56396g66d16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g56396g66d16.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`3`#3`P$1``(1`0,1`?_$`*H```(#`0$!``,`````
M```````(!PD*!@4$`0(#`0$``04!`0$!````````````!P0%!@@)"@$"`Q``
M`00"`0,#`@0$!`0'`````P$"!`4&!P@`$1(A$PD4%3%!(A91(Q<*,D(S)+9W
M&#AQD;%#)349$0`"`@$#`P,"!`,%"`,````!`@`#!!$2!2$Q!A,'"$$B88$R
M%%&A4G&QP4(5D>%B@I(C,T,D-!;_V@`,`P$``A$#$0`_`-5W*/E'D\C)[76^
MM[4U)3TARU=]?5A/;M;FU'W'.@P9PU]R#602=PN<%6E,5K_UH-$1W$OYM_-S
MS>_S?,]EO97,MP.-P+6QLW-QCIE964/MMQ\>U?NIII;6IFK*VVVJX#BH`/)/
MCGC>,F,O(\BH:QAN56_2JGJ"0>Y/?KT`_'LC0H9)LI#VDD\@T@R*<Q2O.95(
MY$>8YGN<4ST[]U]>Z]OQZT&X+V[MYG/KS?-;[\OD<BP;UW,[ZL>K66=;+6'<
M@'Z$;C,H?+5/MJT6H?7\/P':=;58E-D7L:C6$,4HD_Z!PB(SO[R.<Q45'=U5
MJJWNG\4]>MA?&?8KE6YNKAQQ>+CDY'I,'%98Z$@D`[F8=-1KW&A^LMK<B@.X
ML6/\.ND\H-`27[KGQ6N#'B%FR2B[*HHX6M[N56=G(KRO8-OIZO>B?GUCV;[*
MWY2/9RG%TOAU4-;;93M+*B+J=#7HX+,51>A&YE^D_=/(+N`5R.O8_P"_I/+@
MRKK'9HK;'+6RJ9\9R$%*K)DB%-"YB^2.'(C$&1414]4[_P#GU"#\)Y=[?YX\
MG]M>1S\+,J8-_P#'NLJO3;KU5ZV4NH^JGJ!KT8:RX"VC*3T,Q%93_$`@_D9:
M+Q+Y)VNR22-?YY(')RRO@NGTMVC!`)D-;%5C)<><(36!6W@->UZO8UJ2`^3E
M:CAN<_L/\#/F1S/O5ZWM=[FV)9Y]A8QNQLL*J'/QZR%L6U5"I^ZIW*Q9%`NJ
MW.45ZG>S`/)_'J^/`SL+IBEM&7^DGL1]=#VT^AT^AZ/-UTQF&0Z1#I$K@TO\
MBF#[DYZ<A^%%74PHQ=+XS73Z#,VVSBDS3)J4\*'M7'65;XHQQ78587L*.-PS
M%<9X)BN1K1-[HEC_`$B'2)5=RC^13<'$^SSBWSG@'OC)-+8=/.T>[L$S'7&2
MXW.H!N"P63VE'"LWWV(5A7F[.6S8!`K_`*CF]TZ1%&U]\_F$[FRNMU]I'AAR
M7VGL"V!)DP<2QTV!&GD!"'[L^85\:^G,B5D`:HXTHZ"`)')Y.3NB*B3WG?RD
M[QTQ0'SG>GQD<J<!UO6A;,OLSH\AUAL,&.5_DUI;"]@XY>M=40P=_P!9910B
M9Z>3F]^D1RN(W/+C/S<H+&WT/G2V=Q0ACGRG`LB@DQW/\6#*(HHTFVQV4\CC
M5IRIX,G0BRX#R?H0ZO[MZ1'%Z1.-V#L3!-48?>;`V7EV/X+A.-0WS[W*,HM(
ME/35L9GHCI$R800_=,148(3?(IBN:P;7/<UJHE0\'YA#;[S:WU]P"XE[>Y9R
MZ,_T=SL.PGUNFM14YB.=],>;E>61)LL$:2)OF-DR+7R3,_4(;V^JHDDVV^/E
MWHZXEZ_@?QRR>.$3I)<5Q;E1(3+?:&Q2/C@/>X+5X_*F*U.S6L.OD[T;W[IT
MB*IK_P"=YTC?F$\;=Z<,]GZ.V1E&PL.US;1[C,JV6F+V.97D"C@6]G5W&,XO
M9EIVEGM,T@$,R0%/(+R(J+TB:#.D0Z1%7YK<GZ7AUQFVER`MX$6[E893"%BN
M,2IZUK,KS:[F1Z;$\=68P4@P`3[F:)9!!C(0,1A2(U?!>D3L>,.]:'DUQ]U%
MOK'`LB5VS\)I\E+6,.LE*2Y*%8N28\^0K!..7'LAC2H3WJQBN='5?%._9$2=
M^D0Z1,Z$(,J:^3:&::2<YBE,?Q<1RE,]7F.5R(OBXI7+ZKV_/KRI^W7`<AS-
MM_FN979D<EEWOM8`L=[L?5M;3LUMA(!.FGW:'K)QS'V+Z2]*E[_P_`?D(PFM
M]<#V(PM?!,V%DL1&O&I$9]'DT;Q<\M=#*1[!Q,CC#:KF>2^S+%^/@1J>[TJ]
MI?:;%Y_&.+043S-4&^S0;,I="336Q.B92`=#T3)4%G*V*/4MF/CG-US,OU*^
M#JL46VJN[TPW9B.Y&N@8@'9JI*D$Z.9C&L*,-IKC-;2+7U)H:$JLK=D!H]9,
M',Q@$BK@V/A8DCO.6?&C`&51M5?=;Y+_`(G*FYOCOMYQ%7(\%Y;R==.-94OH
MY9RF%5GJ8BM37:!85W-8JUJY5?UC<>Y(N/(6<3C4\IP7&8_[O.VUOB6U*;R4
MN"%E+(&"E-6()TU4Z=P`>/M=%M%B(*>FJA&R#-[MXDE49(\B-!H,=>XT-LB8
M%Y*\()TTXI)E5[45@AHJHYJIUC/)^SCT>-)Q?%8P/-<MF:;\<JR)CXQ+UAG!
M-:K8[+:YW+JJ(-=5TE3=?XES'(9-ENWC^-P\--3M-;OD6$:Z5$;F%84H%"ZL
MQ)UTVD)YL'&86*3B4-?)99RXS6+:7@6*.%;'5?YD>C8Y5>M7$(U6^\[L661J
MN[-&C&KH_P"\_MW@<&;Z.!V6\Q2H;*O1=$RM.K+C#OZ=9[OH'R64E@%6M98_
M2SN-M7&SD>H6H&4,`#L;JI(U.A.GW+J=I^T]09]W'-DFJY`ZR,)I(ZRKJ7&(
MQ4<)WMRJ:S`=CF*B.1A!D7T5/7J#OC-X_E^*_+WPSE<1'Q\?-S,A&70IHUF%
MDJXV]"%L5BP!&FN[3H!I]YFSU.!R$M&I"#3_`*AH?R,O$Z]%DB*'2(L_,?D/
M4<4N,>Y=^6R",37^&6,W'JXG9RW>9V/MT^$T(Q>37F=<9581`.:WNY!O<[MV
M:O2)B4J(^X?C#^0;C]M#<=C/F9%:P]<[KV-:/$8![C%=[5LD&Y:J5[SGNE6&
M.V-M=Q#.55:^;7L+V3NU$1-_<27&GQ8TZ%(#+AS(X9<25'(TL>3&D#:8$@!6
M*K"A,)Z.:Y%5'-5%3I$^CI$@GE(`,GC+R+C2!L,"1HG;H#A(B.&4)=?Y",@W
MM7T<Q['*BI^:+TB9)?[;@;"<P-JE>QKRCXR6?MD<U%>SW=C:X0O@Y?5ON(Q/
M+M^/9.D3:1,AQ+")*@3XL>=!G1SPYL*8`4F),B21.#)BRHQFO#(CR`O<Q['M
M5KVJJ*BHO2)@4T=8S^(_S'U^+ZFDR8%'C/,N]TB.KKRO4-GK/+]E'PF;BIQ-
M5S9<*+260U$QZ.0<F$$J=GC:J(F^J9,B5\25/GR00X,&,>9,F2BL!&BQ(PG&
MD29!B*T80`"Q7/<Y4:UJ*J^G2)B.W_O3:_S4\^L*X[Z]R*TQWCI!S"QB817@
M\TKZ_`\5:<^9;SR.M>]D6RRNWJ(Y'5`I'=D-LJ)$9XD+((5$V.Z*T5J[C=J_
M%]/:>Q:#B6#XG";&@P(K&NESY;FM^OO;V>K6R+G(;@[5-,F&5Q3E<JJO9$1$
M27>D2JKY3^#Y.4&K\9VAJK$HMGRDT!EF(YWJ:=#+5U%OE-?19756][KFPN;.
M57PG5=C%"29"249HXMF`;F.&TI_<1+4`/>0(2$$Z.0@AO(![F/>%[V(YPGN&
MYPW.&Y>RJU5153T7MTB?UZ1,W7S/@V%R]SRPX@:?F^Y!XP<?LWYG;F`%'G':
M7];$=3:NUZX;%8C;ZRI9-K-CL7S56R1$1JJU.R)Y']N'R/;D^I=O<8+BP0MA
MK/(`;/P4!2.<0F$9\]8V11(K7*J)%I,SAK(?V_!]TW^*=(FESI$.D3/YB=3=
MR9L):4$MTH+&D$^&9H3([P\FJUZ&&Y.ZK_'LO7G5]C/&>8?E>*'$UVZX^,'#
M5L%.[T]1UW#]3-KH>A[&2_R+$(Q;H6/\M98WKK'[2!BRWN=Z\C^%#3SLG/E-
M5+A8_:BD4\,]LWZR/22A`LSF6(T?NM"ANZ^3E>GJG6CPSB<_BO%K/(_,^$K]
M+C\*[.?*J:O&NWX];7@6+CNJVLPK";_3#Z]69NLJLKE\;C.$JQ>&Y0KG7J$M
MQ6K]6IO5^URK.FB$`ZD;BITZ:'O"^N,GD;#O#95FE@^7/M[9"SB.?Y#@0>\=
MP8$`3E<V%`@1"D]IK4].RO[*_NY8L]I/*<OW%S?_`-?Y+8N3S.:OJ@,2:T8U
MJ]5-:GH*ZR65$U`)&K$MKK=^+K?C/!\H<0-,G]R5<C]6T+]NNG70G3OIKN/T
M,<2R-B>.R*:NI)310<E,.DOX-9,*ULNNLQNA_5I[!>XI<>1(8HCM5"JUSV]W
M-5>VU@S<'#=<9+[WXG*1*;@Q9#NN9:@$("E7T9CHOZ=H[:]8]XY.6SW?(L7=
ME8JFZMG0':U7WD'<-"I"G<I!773ZQ==TXAF%;!<S%M?1L8@QI2QVSX9ZRTOY
M<!S7L>0M]*F2)T,9G,:Y1QE#V1>RJ[J!O=CQCR?`QMOCG"U\?@UV%/41JK<B
MRHZ]3D.[6U@D`E:BG0D,3ITRSD>2X_E>'JSK>4?.YT.NJE#4E88'<J($5>AT
MU8DDZ:C018]%5\R%OK7`Y@2",'+%1Z%>UY/+[?9M_6Y'O5SE1?5?SZT$]D_'
M<[B_DQXQ3FU.C4>0N06()(_;Y:`DZDG4'N>_>6;DV+\+?9W!KT/]NJF79==W
M9%T.D2E+GE-_ZJ.<_#/@)6JEAA6)72<P.2D8:^]#7$=<G,'6V*W#1?J&#(\G
M\VF"141R28I.WX+TB*O_`''G'9,GT[I[DQ45[2V&K\GDZWS:0(+GE?A.P_`U
M'*EO:BHD2GS*L&!GEV1K[AW\>D2P7X:^1[N1G`_59[:P6=FNH&'TGFCBE:26
M23@H(@<7L9"=_=5UM@LNK,XCO]0ZE]55%Z1+4.D2#N3O_;7R%_Y';9_X"O\`
MI$Q?_!'R&TCQMY+[#S'?&SL3U5BUYH&9C%1?9C8?;*R=D!<WP>U'5"EN&\39
M3ZZM.9$>K45@G>O?LBHFES</S'<(\#H2`U;LV)R0VM<O%4:\U)I.':YE?YME
MEFOTM!2ALZVO-2UP;"S((3R/.\WB]?9"<GB)R)77\8OQ2[D)R#F<].;E6#&<
M\FYGDVSL%U`\P)=S'SW,)]A;&SG.?IBR(M,E":W*M14M*24*2C#RE"\#`O1+
M7/E?V';:P^._E1DU%*+"MI>NOV;%E!<YA0,V)?TN`S2B>U4<,C*[)#*UR+W1
MR)VZ1*$_[:O`JR?N/DWL@X0OL<1UO@6%U#G,:Y\2-FV17=O;N`JM51J9,&B,
M545%\45/P5>D37STB'2(=(ATB<UF>7X_K_#\JSO++`55B^%X[=97D=F9405?
M1X_72;6UF/[JG=L:#$>_M^*]NW2)4O\`$-C%ULW7N_N<FR:MS,RYS;<O\SKH
M-DQ)#ZG26'FG8;J_%D;(1[VU\:N#+5K%_0:.\+NRIV7I$SV:3G'^+_YEY.%6
M)BT^MP[7L]83WRGN!$/I3=SX4W!;64K5\'Q<;^[TTPKO5&DK2)^2](FZ#I$.
MD3/-0B;*?%>0T2,%6^T:3-)[8!]T\%548PIRJBIW\1L>Y?X=>;+V6SJLBWB^
M5OMHIPVJ]&VVU@JJ=OIMH-"[$,`=J*S:'7323%GU'2Q1]#K_`(_W1_M'V6&O
M'!QZIKK;-[V1&D4,QQB_MJDB5\R,2/821P46;,DQ1UAB(X\EHV]D54&QW76;
MVFS/%+:J_'\#'RN7Y2VM\6W<?VM"TVHR6L*]7=T%3.#9:$'0Z(ATEUMOS>9\
M19<G,QL3C,%5##TS9?8R$&H:G:$#-M516220=S'J!"]KJC9>L;N>3#JN=GV&
M.G205=_C$<EY'D`C'>QD:SC5RDE0;.$[NPBHB#5Z*HWN8O;K6P^W7NS[)\U?
M@^.<?E^2>WPR'&)F\>ARB$#G2N^JHFRNVLZJW0+OU:JQD;06GC.?R^'R-6`Q
M\NVM3;CW@JKJ1JIT;3N#JI'70Z$=Q)WU3C.PK*^JKS+Z,>+QH'U-GCV/Y#(6
MMN\RN:T228M?"ARVJ6%#%((-YC&%YJGBUB*BN<W9_P!M,3S_`,CY+%YWS##R
M..P,?=;BXN<QIR<W(J4-7553:Q>M`VPN]B!B-%0$%F6LS?+GS,*["X[&HQ\.
MP!,F^E6M]&JP[68D:``C=H-?I]#(OW1981=N?'BOL\1NWRRSY]+>,-<52&$X
MPR!9:@1UE5D]]SOY9XQ!HK5_4Q.R=1S[M<QX=R7J%7OXSDT=K[J<C6Z@%=VX
M>LO_`':3KN.VRIEZ?J0:2X>1W<K@\9C>/Y>1BY5!"V5VU*48H!M3>@U0@ZZJ
MRMJ0-2#W,/Z#:X6]]9-7VE4F5*J."091N;]MLG>0R"<YCV_A^"]:7^Q.3;7\
ME_$6L]/U<SG[&U1E=2IQLNPE64D,`=H/7IKUT/28IRM>WA[Q_34/[U$N\Z[X
MR+9Y-_>U&+45UDV03X]50XY4V5[=V<MZ#BUM140S6%E/DD7T9'APX[R/7\FM
M5>D3-[P'XQ6GR$Y)R1^1#.MR\DM(SMY[<R'%-3MT9LIVM+0^D\#6!24=?>V"
M4-K)M*^/(K`Q1A8\06RJPI%:YST5$1U-T_$?1[,U1G^#R>87.O,S7V,68:C&
M]F<B79=@-CDL0"V&*KE6.3<2$"UJ(F21(IRC\QO[#[L>QR(Y$2D[^WOWW9:D
MY5[,XP9D\M3'W'03W1*B9V$M;MS4)+%\ZM5AE:H9<[%R6HRHGZGDK0M[*J)T
MB;->D2#N3O\`VU\A?^1VV?\`@*_Z1,AG]N?C]#DG+#;-=D='3Y!7KQGL"?0W
M=9!MH?N?U$UX-2)&G@D!0BC>YODB=_%RI^"JG2))WSC?'C6<=\IQSF+QSQ],
M'P#([^NKMCTF%`2F@ZVV:DILK%,]QN-6-`/'*O*984"5([1@B7(0O9V=-[-1
M+T_BBYYPN<7'*#-R:=$9O;5;*W$-Q50_;`2RG)%<E%L.%$;V1E3G4.*\SD8B
M,CV(98&HC!,5R)+_`,EFI+?>'!#D]KC'HKYV0V.L;.^H8(F*21/N<&F0<ZK:
M^,QJ*Y\JQEXVT`VIZN>1$_/I$S;_`-N#MVJQKDGN?4EC-'&+MW5=/D.-#*O@
MMC=:SN)DB77@:[U=*?CN7RI2-_'VH9%_R](FRSI$.D0Z1/-J;BHOX`K2BM:V
MZK#DDB!8U,Z+8P#%A2C09@Q3(931R$B38Q`E1'*HRC<QW9S51$2FWYIMI9%,
MU%J/A7K*6C=K<XMJX[JJ,(3D4U?KB'<5$K.;:2UCVF#7E-+@Q#N7LQ\(\KU[
M,=TB2ABOQ28?A>-4.(XOS/\`D+QS',;J8-+2T..<EW4=#4UM?'9&BP*BG@X:
MR'65\<0T:(`T\!L1&I^'2)0/\XG`-.-W](-Z8_M'>6W8.=3+76V;Y;O#.$V#
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M;_WG/`\?_H%=_H<C8BI=ELO_`-I!U&,2>M=(.F[])R7`>PJ%1!:J_6X[.3/Q
M`EC5/N4,NJ[M"-=I[D:G0]U[KH>L;G$MTPX&8ZWQ9J2`0<85L2>^(YBP95_<
MQ)!,@*]6D8\@HDJ6Z*-7([T"JI_BZW;\8]V*,/R;@O'E#K@<?HEC5D&I\B]&
M.23UU*UV.:5)W#["PTW2NY#E>,Y/`Y5L^E_]<SRNUM`RUK5L]-%).X#[2S'3
MJ3H>@D>6.YEOL)L:L22/NN.V29-03;$G9[85B=07T4/@5Q$?#D2`S!)Y)V1I
M?R:B=8+RONTG(^'9&)<S)G8%_P"[HMO;32NPE<E0=W>LLEZZGL+/Z0)<+O)<
M/#Y6S/\`'<?:+\046*ZJ%8H0*[-BDZD)N1@3HVJZ_75=<OS*1EY%L;<B$O6C
M&.QN?%HG7P@-1@9%BQB-9]T"-J,<=$3ZEC44B>XBO)IA[K^[=7FN-:;K=N4@
M!R<M@$&8E8Z&SMML31=;-!^X4#>`Z[K<=QL9PP=]-W^51V7\%'8#^"C0*.@&
MG;L.+=;,R+D!@?T8WOCTTFRNI;T:OB"%`JIK7'*O^5I99Q"3O_F(U/SZCWX;
MOR/N%\O?&[N+1CP_%'*R6.AT6FK%N4VO_#U+K*JUU[%ZU/6?UY_T\3@;A9_Y
M'`'?ZEAH!_8-3^1EWG7HVD12@?YWN<^)ZBXUY)QDP3+:Z9NG>$=F/9%45%@.
M3981JU7_`%&5V5^V$9Y:HV5@`VHBQS(TLD$N21B*T*KTB6O<,L%U[K+BGH#`
M=6W--D6$8OJW$8%5D-!-CV%9D$@M3'GW%^&7%(0)27UU,D3"]E[^Z=W?LO2(
MS72)@F^1&SK>(7RUYKM?2EO4VI\8VA@F_(\&HGQ3Q:_*[P,'(<\PNP)#<\$1
MUO:_7I(`OJ.+9HU[4[]ND3:YQQY-Z8Y5ZUH-HZ7S6GRFDN:V)+GUD>;&_<>)
MV)A-=,QW+J-I73Z&\JY*N"8)F-1SF^8W/$YCW(G%\X-J:]U1Q4W_`'>P<OH,
M5AS-.[)J*MEQ9Q(4J[NK?#[BLIZ2EB&(V3:6UK92A@``#"$>1Z>G;NJ(F2C^
MWOV;@.LN9>45^?Y91X@3/=$7&'XI(R"RBU4&WRF/F&$WC:"/.FD#%^Z3*RKD
MDCB5Z..H'-8CG^+51-H.V-78+O75^;:FV'5`R'`]CXS8XUD$!7,5)%;:1U8V
M5"D>)$C6$$WA)B2&(KX\D0RL5',1>D3"7A63;G^&'Y#K*NMFV-U48?:MHLM@
M@18D/=''_*)8Y===0!J_Z1;4E>`<Z'W5S85]`)'>O@TR.1-RND>0FEN1^%56
M?Z6V+B^P,:MX09:$I+.-(L:Q3,1SZ_(*52):X_;1G+X&B3`A.)Z*CF](F3GY
M$.`F\?CRY,0>=/$*FGS-1U><-V6$5#`D62Z5R.7**7(L9RJF@M62?4.2MFR(
MXY+4]B+"F$@R5$C8YC(FC/@I\B6A.=FOZRZP7(:V@VA$K8Y,]TY;V<5F7XO9
MM"GUQZV,]PBY/B1#M<Z):Q&/"02M0R`/YA8B/STB48_+!\M.MN,6L\RT[H[,
MJG,>3645%A0M=C$^/:0-+PIT8D>PRK)[&$0L2-ET2,]_VJJ\UE)+\#R&,`-$
M,B/WPIPS&^,?!3CMB^67%3B=3@VD\1MLQN\BLHE/65US=U`\LS"PM[2R-'C1
M_+(+B64QC/3R>KG.7NJ](E+?%3D1K+GO\UF9[CD936/P+0&G<@Q7BY5V\D$)
M<OE!LXV-76844&Q2,:5)M!Y/=6(1M9]6V":(]S4]ARL1-._2)6C\OFNL*V7\
M>_(BMS*WI*$F+XK_`%%P^UNYD:$,.;X%('D-#!@DDD'[MCD2Q2U0Q,\B&2>K
M&HJN1.D2@OX"N=>!Z+RG8?&;<N7U^&XAM:WK,SUED&26`JW&JW8H80J/(,:L
M+&6X<&I-F-1$@$B%,087RJ]PO+W3B:Y$V'??*7MW^\5?;[=]X[_<(G;[3Y>'
MW3O[W_UWGZ>__I=_3RZ1$\Y'<3`[2LBYO@\R#2YF40V6\&?[@JC(_IQ(($E\
M@`RDKK=@6-&I/;>,S&M1Z-5%>O.+Y@_`_"]]N4;W%]NLC&XWW&9`N37=N7%Y
M`(H5'=T5VHR515K]38Z6JJ"P(5-AS#Q_R<\:G[/,#/B?Y2.I3\-.FJD]>^H^
MFO:)(WB[R'JY2"77Q9S8Y$<PT:^QHHE5BHK'#(ZX&YS>Z=T1S47_`,.M`>#^
M(_S&\1S4P\CQ4<E@4.-C+R'''0*=5*.V4"5'0A;%UZ:?:.DRI^>\?L`L%X5C
M]-K_`,QMZ3TH''+D##F`FLU];B,$WOH]MSC2O0G=7*_NV]]7JY>_?\^I,\?^
M.GR@XW.IY!/&>4QKDLWD?O>/(W=R3LSB&U/?IU^LHVYCA&.CWJR_716U_+59
M\K>->_PN1X]=6A'HQ[/6YQI$<P@W"(QROO.ZM(-ZM7T]47JW9/QK^4%%HR*O
M$^1S,A58?=G<<`0RE64FS.UT925.B]C/M?-<,/\`WHO_`"O_`(+/T@<2N0=Y
M+'%-AT>DC.>B/EVU_2"B`;W1/<*D&=833(WOW[#"]?X)U'C_``@^7_GN>O'<
MCP>-Q'#%A]U^?B>DO7HUGH77W6$=]%J;_A4&58\CX#%3U$M-EGX*VO\`,`#_
M`&RR#CWQYI='5,LSY;+S,;L01W=Z@5"`482H0=34B>KBAKAF_6]SU]R01$<Y
M&HUC&=:_BA\3?&/C-X[>RWCDO/N111F9NS8H13N7&QE.K)CJWW,6.^]P'<*%
MKKKP3G>>NYFT#39B(?M7ZZ_U-^/\@/S)F[*L8I<UQC(L.R2*6=CN5T=KC=]"
M#.L*PTRGNX)ZVSBBLJF5!M(!)$*2]B&C&$<2KY,>UR(J;<2P2O\`B?$1\;D-
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MO6,0M9'RUM/81QJ1>\>3'-'<GHYBITB?G8?Q?\#]M;`R3:6R^/./YOG>6W$B
M^OKS(LGV!8)+M)31M.<%63+OLU<)[1)_)C1P@;^3$[](G,3?B(^-FP`L>1Q&
MUDT;E15^D=DU>7NGJG8\#((QT[+ZIV=Z+TB-IH;COIWC)A1]=:/P],'PN1>3
MLC?1,OLGR`++>QC08DN1'DY5=7LZ($D>N"U`"*R.SP[M8CG.5R)'W('A!Q2Y
M4Y!C&4\@=*XOLS(<-K9E-CMK<2+R%*A5$^6.=(K#+26U6RS@_6#]T8I:'8%[
MR*-&*4GDB1AAWQ<\!M>9SC.RL"XW8EAF;X==U>18]?8Q=YM1FAW%++%-K9)X
ME=E$>NLQ@DA:Y0R@G`5$\7L<U5141]R#&89`F&PH2L>,HB,:09!D:K7C(QR*
MU['M545%145%Z1*W-N_$AP*V_D;LUEZ4!KG.G2W3TS32F1Y%J*\'.>OD^<,>
M%6-73-G$>ODX_P!(IG.]5<O2)RLCXD-&VT-*;+=_\Y<XQCP:)V)95RVV9)QX
ML9J>/TIXM=)K)4B,K.[5:\SN[5[=(DA8!\3WQV:W8+[#Q1U?:2!^KIV<0;'8
MTTQ%7R>8QL\L<B12D=ZN5$:BK^72),N_^$O%WE+.Q:=OS4]=L=V%UTFIQJ%9
MW^85M+6P)<B-*.']OT&0U-%,>I8@_$DB.4C&M\6N1OITB03+^(CXW9B"[\3M
M>PR`(A02:B?F-'-"5$[-**=39-`F,(W\G(1%3I$?#`,#Q75V$XOKO!JQ]-A^
M&4L''L;JB6-I;/KZBM"V/"BOL[N;8V\YPA-1%+(.8S_Q<Y5]>D15]T?'3PPY
M$[!L=I;KT?5;#S>U#4QYMI=Y5G[8;QT=>&KK/9Q^!ED/'(CX\&.QBN#$&XBM
M\GJYRJY42.I/Q%_&W+COBFXC:Q01&^+UC_N2(96]NW;ZF)?@DIW_`#_7Z_GT
MB>=_^/GQQ^'M_P#376>U]']M]K^HNX/;^U>_]5]G]O\`J%X_9_J_YWTG;Z?W
M?U^'EZ](EEO2(=(ATB'2(=(ATB'2(JF]LXV+#V-J75^O,AKJD^PYDM;YP:5L
M[(:?'J@@I%O=Q9\R2>NC`)7^Z,35B*1"B5R$_!$1&K3T]/\`UZ1(OV1(VR`^
M&)J^!B\Z.7*(@\W7(SF"^-BZ]OJC5GM&%Y2$17=^WN$14;XL<BN[(DH=(ATB
M>'DF2T&'TD_),HMH5'158FFL+2P*@(D49"C`-2$7OZD,5K&HB*KG.1$157I$
M].',C6$2+/A&9(ASHP)D20/O[9XTD33`,SNB+X%$]')Z?@O2)"G([/K_`%CJ
M7(LSQFPJ8%Q6/@"AMMZPUJR<:?,%`'"A@%/@M%.>20CV$(AAM:-WD-W?NB)W
M>LPY,#`,13,[$UKEAZ.%-R&:<,>.]UM8#^NF1T!%$".$4$LA0#:UB(C!ITB=
MSTB'2(=(ATB'2(=(ATB'2(=(ATB'2(=(ATB'2(=(ATB'2(=(E=&*KEFZ=X[A
MV1C]ZF(8EC,-^N*G8JQHTT]-34[GR+Q,1CV*/@);6LD3CFFF:\<*&9?%CB%:
MK$1AN*5WF&1:9J+K,;BPR&7-N,C?275JO_R-KC8K:0"HF2GN1'O^H8)[AN=W
M7V59ZJG;I$X7!,BV7FO)6]CERV2N'ZXQM8N98[5*/]H@RV^20M9C,(J`%*MY
MU)"5I94V0J/66`C6#")6CZ1.WW)L7*$S;!M):XF#J\QSMLBTN\G='#,?AN$U
MZE^XVL*+):^*:YFI&*.)[J.&Q[.ZM57,5$3SM7Y3<0=];0U&R^N\FQ?%\3Q.
M\CSLBLB75M6W\X866<-]J5$,\%B&4,WL._0$@WH)K&JK41.(Y0LO\^SC5&B`
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M8<&"UC[;*,B.%'GB8Y1C(U2*Q%-),\<<*>9.[41>:B;G.6<DH6)`V;D-YB^K
M*%F0[#97BKZ"BE9G;_41JK%Q1J0`S'K01G,D/BSI,US'!(UQ%>KEZ1/5YAYK
MF.$:Y)/QK)3XM]=*KJBM-1JUV36^0SYJ/;!"0L=Z5U1!IHD@Y"1U65(.HA-4
M3$?[J)U&`X+N23>X-GV9;/M8L8./.C9!J]M?&6K<I:MD:N^LG,*Q\B_9(=]5
M82'#=_NNX@>`6_J1(SY:YUL>B-A^*X/?SZ:\R[):JNQ6HQ0H/W#D#0^)+N=;
M3),=5JZR,>3&BQ@"5$,]Y3')[3$'TB<I9Y3NDO)+'\*QK/I-M:Q<3E6>R*QX
M0)K7"%LXADC("N"*/+GK0QY4<S'RC_43I;Q(K@C>1@T24.+5MF>3R]K9199I
MD688!)R]]+K^9DSXA)DP5&Z4"YN8;842#$B5<^49C`B"-@D]I4\4<U55$F#)
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M`'&C56<ZYQES\ZEP8U[:S+JWO:ZKE-LWW-_=V#94O(LCN"`8LFQ%&CBC1HT9
M?IHXD(]SRD+_`"D3[LKP++J?=:[CQ*AAY>>?K8^"I3R[J-1K46PK@5E!MRRI
M8BM)328ZO%)0*/E#5J*P9$<J-1.ATKJ61KB+DUYDEH#(=B[!N29%F]]&$\,)
M\MZE6)3TXBHAA4M0PSF`\T1[_)7*C4\6-1%ZPVUR[-N1&U]M8UBH,QI<.`73
MN,#+>Q*9L2?7NB3;.R!*FA*!]82<TR2'A0DAC)+%8(J*Y$1&.U#JV1@:93DF
M23XMWL38=RZ_S*XA"**O&1J/96T%(R1_N&4=%&?[05(B$*O=[D;W1C42.)VO
MMJ56Q-P;DI:?%+_,)M;C6)ZII;:WDB@!Q:"2,;(#61V@C+`GV)_,@QL+X^35
M1ST:Y>Z)*>!8)80LAR#9>9,@?O\`RZ#5U9XE;(+-JL3QNJ'YPL8J9T@$8T[S
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M8B=U1&]T2-86DMHX_I3::USJ:=OO;L^;-RBU%8^S$CQ+6R^G)45EI*"!&`JZ
M"0?V>[1M:8KO'_"Q>D1@=,X)::\PBGQVSDPV.@5M;!BT=1W?24((45&%#$EF
MCQYMK/LII"RYLPS6>_(*O@,8VM;TB+,S4?(;[+R"J`RL8K'9_D^3Y%5WL.U,
M[*,I%.C#KZ3'OJO;;#QJC!6QV#<1ZK)8U7!8UC7*9J)._'G6V1ZRP"FH,B/7
MQ3PZN)%9CU*])-97R?=DS;2SE6)`!D6E[=6$U[SO1&QPB8((6J@W%*B3UTB'
M2(=(ATB'2(=(ATB'2(=(ATB'2(=(ATB1YM+^H_[,M?Z5_8OW=[3_`*7[][WL
M^Q[!O<^W^W_M_N_N>'L?4?[;R[^YZ=(BX<%OO/\`1Z3]=]G^A_==_P"Q]/\`
M5_N+[K]>;[U^ZO>_VOUON>U[/M?J]CQ\_7MTB.ETB'2(=(ATB'2(=(ATB'2(
..=(ATB'2(=(ATB'2)_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
